Breast

The Breast is a peer-reviewed, fully open-access journal published by Elsevier as an official journal of the European Society for Medical Oncology, founded in 1992 and devoted to translational and clinical research on the prevention, diagnosis and treatment of breast cancer at all stages, with a 2025 Journal Impact Factor of 5.2.《乳腺》（The Breast）是由（Elsevier）出版的同行评审期刊，为（ESMO）官方刊物，完全开放获取，1992 年创刊，专注乳腺癌各阶段预防、诊断与治疗的转化研究与临床研究，2025 年期刊影响因子为 5.2。

Scope

• The journal serves researchers and clinicians as an international, multidisciplinary forum on pre-malignant and malignant breast disease, balancing basic science with clinical papers.本刊是面向研究者与临床医生的国际多学科论坛，覆盖乳腺癌前病变与恶性肿瘤，兼顾基础科学与临床论文。
• Epidemiology and prevention, including risk factors, risk communication and preventive strategies at population and individual level.流行病学与预防，包括危险因素、风险沟通以及群体与个体层面的预防策略。
• Translational research built on new technologies, molecular biology, genetics and pathology, linking laboratory findings to patient care.转化研究，依托新技术、分子生物学、遗传学与病理学，把实验室发现连接到患者诊疗。
• Screening, early diagnosis, follow-up and response assessment, drawing on imaging, nuclear medicine and other diagnostic technologies.筛查、早期诊断、随访与疗效评估，运用影像学、核医学及其他诊断技术。
• Medical oncology, radiation oncology and breast surgery, including trials of systemic therapy and locoregional treatment.肿瘤内科、放射肿瘤学与乳腺外科，包括全身治疗与局部治疗的临床试验。
• Psycho-oncology and quality of life, together with specialised sections for epidemiology, imaging, prevention and genetics, pathology and translational research.心理肿瘤学与生活质量，并分设流行病学、影像、预防与遗传、病理及转化研究等专职栏目。
• Accepted formats are original research of up to 3,000 words, reviews of up to 5,000 words, short communications, viewpoints and debates, and correspondence on published work, while case reports are no longer considered.接受不超过 3000 词的原创论文、不超过 5000 词的综述、短通讯、观点与辩论，以及针对已发表论文的通信；病例报告已不再受理。

History

• The first volume appeared in March 1992 from Churchill Livingstone of Edinburgh, the medical publisher whose list was later absorbed into Elsevier.第 1 卷于 1992 年 3 月由爱丁堡的医学出版商（Churchill Livingstone）出版，该社的医学出版业务其后并入（Elsevier）。
• It is now an official journal of the European Society for Medical Oncology, an associate journal of the Australasian Society for Breast Disease and is affiliated with the Hong Kong Breast Oncology Group.本刊现为欧洲肿瘤内科学会官方刊物、澳大利亚乳腺疾病学会的协作期刊，并与香港乳癌肿瘤学会保持隶属关系。
• Six issues appear each year, with volume 82 dated August 2025, and articles are also released individually on ScienceDirect and the journal's own site.每年出版 6 期，2025 年 8 月为第 82 卷，论文同时以单篇形式发布于（ScienceDirect）与本刊网站。
• The journal is gold open access with no subscription charges, levying an article publishing charge of USD 3200 for research and reviews and USD 1420 for short formats, with a 20 per cent discount for ESMO members since January 2023.本刊为金色开放获取，不收订阅费，原创论文与综述的文章处理费为 3200 美元，短篇体裁为 1420 美元；自 2023 年 1 月起（ESMO）会员可享八折优惠。
• Authors may publish under CC BY, CC BY-NC or CC BY-NC-ND licences, and a CC BY licence can be applied for after acceptance to meet funder mandates.作者可选择（CC BY）、（CC BY-NC）或（CC BY-NC-ND）许可，录用后还可申请转为（CC BY）以满足资助方要求。
• The 2025 Journal Impact Factor is 5.2, after 7.9 in 2024, 4.254 in 2022 and 4.38 in 2021, ranking 9 of 143 in obstetrics and gynaecology and 81 of 333 in oncology.2025 年期刊影响因子为 5.2，2024 年为 7.9，2022 年为 4.254，2021 年为 4.38；在妇产科学类别列 9/143，在肿瘤学类别列 81/333。

Editors

• Fatima Cardoso of the ABC Global Alliance in Lisbon is editor-in-chief, with Karen Gelmon of BC Cancer Agency in Vancouver as deputy editor.主编为里斯本（ABC Global Alliance）的（Fatima Cardoso），副主编为温哥华（BC Cancer Agency）的（Karen Gelmon）。
• Specialty editors cover epidemiology with Sabine Siesling in Twente and imaging and early diagnosis with Alberto Tagliafico in Genoa.专职编辑按领域分工：流行病学由特温特的（Sabine Siesling）负责，影像与早期诊断由热那亚的（Alberto Tagliafico）负责。
• Prevention and genetics sit with Suzette Delaloge at Gustave Roussy and pathology with Frederique Penault-Llorca at Clermont Auvergne.预防与遗传由（Gustave Roussy）的（Suzette Delaloge）负责，病理由克莱蒙奥弗涅的（Frederique Penault-Llorca）负责。
• Breast surgery is handled by Jorg Heil in Heidelberg and Marie-Jeanne Vrancken Peeters in Amsterdam, medical oncology by Volkmar Muller in Hamburg and Mafalda Oliveira in Barcelona.乳腺外科由海德堡的（Jorg Heil）与阿姆斯特丹的（Marie-Jeanne Vrancken Peeters）负责，肿瘤内科由汉堡的（Volkmar Muller）与巴塞罗那的（Mafalda Oliveira）负责。
• Radiation oncology is led by Philip Poortmans in Antwerp, translational research by Serena Di Cosimo in Milan and psycho-oncology by Gabriella Pravettoni, also in Milan.放射肿瘤学由安特卫普的（Philip Poortmans）负责，转化研究由米兰的（Serena Di Cosimo）负责，心理肿瘤学由同在米兰的（Gabriella Pravettoni）负责。
• Society representatives include Elisabeth Elder for the Australasian society, Delaloge for ESMO and Beat Thuerlimann for the St Gallen conferences, and the board draws members from Europe, North America, Asia and Australia.学会代表包括澳大利亚学会的（Elisabeth Elder）、（ESMO）的（Delaloge）与圣加仑会议的（Beat Thuerlimann），编委来自欧洲、北美、亚洲与澳大利亚。
• Review is single anonymized, with at least two external reviewers per accepted-for-review paper, formal recusal for conflicts and a single appeal, and generative AI text is not accepted.评审采用单盲方式，送审论文至少由两位外部评审人评议，存在利益冲突的编辑须回避，申诉仅受理一次，且不接受生成式人工智能撰写的文本。